Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer

Abstract

Disclosed herein are methods, compositions and kits for treating non-small cell lung carcinoma (NSCLC) in a human subject, wherein the subject has been previously treated with an immune checkpoint inhibitor, the method comprising administering either an interleukin-15 (IL-15) protein or fusion protein derivative thereof, or an interleukin-15:interleukin-15 receptor subunit alpha (IL-15:IL-15Rα) protein or fusion protein derivative thereof, and a PD-1 inhibitor antibody and a taxane. Further disclosed is a treatment regime for administering either the IL-15 protein or fusion protein derivative thereof, or the IL-15:IL-15Rα protein or fusion protein derivative thereof in combination with administering a PD-1 inhibitor antibody and a taxane.

Dependencies are inferred from the claim text.